BofA Securities has recently reduced Omnicell Inc (OMCL) stock to Neutral rating, as announced on October 31, 2024, according to Finviz. Earlier, on August 2, 2024, Barclays had raised the stock from a Underweight to Equal Weight, setting a price target of $39 for OMCL stock. Barclays also initiated Underweight rating with a price target of $33. Additionally, Wells Fargo raised Equal Weight rating on November 3, 2023, with a target price of $28. Piper Sandler analysts, in their report published on November 3, 2023, also raised Overweight rating and set a price target of $70 for Omnicell Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Omnicell Inc (OMCL) Stock Trading Recap
On Wednesday, Omnicell Inc (OMCL) stock saw a decline, ending the day at $33.34 which represents a decrease of $-2.37 or -6.64% from the prior close of $35.71. The stock opened at $33.92 and touched a low of $32.33 during the day, reaching a high of $35.65. The volume of shares traded was 1.10 million exceeding the average volume of 0.46 million.
Sponsored
OMCL Stock Performance and Moving Averages
In recent trading, Omnicell Inc (OMCL) stock price has shown some volatility, fluctuating -11.85% over the last five trades and -21.37% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -25.06%, and it has plunged by -27.52% in the previous three months. Currently, OMCL is trading at -13.12%, -19.33%, and -16.17% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, OMCL, a Healthcare sector stock, is trading -40.19% below its 52-week high but remains 32.72% above its 52-week low. The Average True Range (ATR) (14 days) of 1.57 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Omnicell Inc’s Profitability and Valuation Ratios
Omnicell Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.49% and a profit margin of 1.13%, with a gross margin of -25.06%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Omnicell Inc’s market capitalization stands at $1.56 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 127.11, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 16.82. Additionally, the Price-to-Sales Ratio is 1.40, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.24, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.31% of Omnicell Inc (OMCL)’s shares, while financial institutions hold 100.43%.
Notable insider trades include PARRISH MARK W, Director at Omnicell Inc (OMCL), who sold 12,000 shares on Dec 10 ’24, at $47.30 each, totaling $0.57 million.
